Precise pathological diagnosis is crucial for proper management of patients suffering from cancer. There are approximately 100 known tumor types of the central nervous system. Due to Large number of tumor type standardization of the diagnostic process is very challenging. Researchers are now working on a completely different approach which is DNA methylation-based classification of CNS tumors across all entities and age groups. They have shown its application in a routine diagnostic setting. Results have shown that the availability of this method may have a significant impact on diagnostic precision compared to currently available methods, resulting in a change of diagnosis in up to 12% of prospective cases. To increase the accessibility, Researchers have designed a free online classifier tool, no additional onsite data processing is required to use the tool. Results have provided a blueprint for the generation of machine learning based tumor classifiers across other cancer types.
- Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases
- Global Top Players in Intraocular Lens (IOL) Market
- How Robots Are Introducing A New Dimension To Healthcare Service Delivery
- Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment
- Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases
- Which Countries Top the Chart in Global Pharmaceutical Market?
New method for classification of CNS tumors
Mar 21, 2018 | Reading Time: < 1 minutes
Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval
FDA Approves Eli Lilly’s Jaypirca for Relapsed Mantle Cell Lymphoma Eli Lilly has received FDA approval for Jaypirca, a non-covalent BTK inhibitor, in relapsed mantle cell lymphoma (MCL) patients who have relapsed after treatment with other drugs in the class. Adult MCL patients who have previously received at l...Find More
ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs
Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American S...Find More
How is Nanomedicine Transforming the Dynamics of the Healthcare Industry?
Over the span of the last decade, new and revolutionary technology has been introduced into our daily lives - nanotechnology. It has been applied in multiple fields through an integrated approach. With a rise in the number of applications and products containing nanomaterials, nanotechnology now is a very integral ...Find More
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.